| Title: |
Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium |
| Authors: |
Bansi-Matharu, L; Phillips, A; Oprea, C; Grabmeier-Pfistershammer, K; Günthard, HF; De Wit, S; Guaraldi, G; Vehreschild, JJ; Wit, F; Law, M; Wasmuth, J-C; Chkhartishvili, N; d'Arminio Monforte, A; Fontas, E; Vesterbacka, J; Miro, JM; Castagna, A; Stephan, C; Llibre, JM; Neesgaard, B; Greenberg, L; Smith, C; Kirk, O; Duvivier, C; Dragovic, G; Lundgren, J; Dedes, N; Knudsen, A; Gallant, J; Vannappagari, V; Peters, L; Elbirt, D; Sarcletti, M; Braun, DL; Necsoi, C; Mussini, C; Muccini, C; Bolokadze, N; Hoy, J; Mocroft, A; Ryom, L |
| Source: |
The Lancet HIV , 8 (11) e711-e722. (2021) |
| Publication Year: |
2021 |
| Collection: |
University College London: UCL Discovery |
| Description: |
BACKGROUND: Weight gain effects of individual antiretroviral drugs are not fully understood. We investigated associations between a prespecified clinically significant increase (>7%) in body-mass index (BMI) and contemporary antiretroviral use. METHODS: The International Cohort Consortium of Infectious Diseases (RESPOND) is a prospective, multicohort collaboration, including data from 17 well established cohorts and over 29 000 people living with HIV. People with HIV under prospective follow-up from Jan 1, 2012, and older than 18 years were eligible for inclusion. Each cohort contributed a predefined minimum number of participants related to the size of the specific cohort (with a minimum of 1000 participants). Participants were required to have CD4 cell counts and HIV viral load measurement in the 12 months before or within 3 months after baseline. For all antiretroviral drugs received at or after RESPOND entry, changes from pre-antiretroviral BMI levels (baseline) were considered at each BMI measurement during antiretroviral treatment. We used logistic regression to identify individual antiretrovirals that were associated with first occurrence of a more than 7% increase in BMI from pre-antiretroviral BMI. We adjusted analyses for time on antiretrovirals, pre-antiretroviral BMI, demographics, geographical region, CD4 cell count, viral load, smoking status, and AIDS at baseline. RESULTS: 14 703 people were included in this study, of whom 7863 (53·5%) had a more than 7% increase in BMI. Compared with lamivudine, use of dolutegravir (odds ratio [OR] 1·27, 95% CI 1·17-1·38), raltegravir (1·37, 1·20-1·56), and tenofovir alafenamide (1·38, 1·22-1·35) was significantly associated with a more than 7% BMI increase, as was low pre-antiretroviral BMI (2·10, 1·91-2·31 for underweight vs healthy weight) and Black ethnicity (1·61, 1·47-1·76 vs White ethnicity). Higher CD4 count was associated with a reduced risk of BMI increase (0·97, 0·96-0·98 per 100 cells per μL increase). Relative to lamivudine, dolutegravir without ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
text |
| Language: |
English |
| Relation: |
https://discovery.ucl.ac.uk/id/eprint/10136301/ |
| Availability: |
https://discovery.ucl.ac.uk/id/eprint/10136301/3/Bansi-%20Matharu_Association%20between%20newer%20ARVs%20and%20increase%20in%20BMI_14Jul_FINAL.pdf; https://discovery.ucl.ac.uk/id/eprint/10136301/ |
| Rights: |
open |
| Accession Number: |
edsbas.820BCFCD |
| Database: |
BASE |